Enter your keywords

Transfer of prescribing from private provider to NHS GP

This publication aims to provide guidance on what NHS prescribers need to be aware of when they are asked by a private healthcare provider, and/or patient, to take on the regular prescribing of a medication for a patient, including medicines supplied under formal shared care agreements. Based on suggested best practice it discusses the principles […]

Considerations for Sustainable Inhaler Prescribing

Inhalers account for approximately 3% of all NHS carbon emissions. Reducing the carbon impact from inhaler prescribing has been identified as a significant area of focus for delivering a net zero NHS. This document aims to outline strategies that can be considered to promote optimal respiratory care, while minimising the environmental impact from inhalers and […]

Optimising the use of morphine 10mg/5mL oral solution in primary care (Update)

Opioids are effective for acute pain and pain at the end of life, but there is little evidence of their effectiveness for long term pain. This document supports primary care teams to review patients receiving regular large quantities of morphine 10mg/5mL oral solution and includes advice on how these patients could be managed. This publication […]

Budesonide orodispersible tablets for maintenance of remission in eosinophilic oesophagitis

Budesonide orodispersible tablets (Jorveza) are indicated for induction and maintenance of remission in adults with eosinophilic oesophagitis. A NICE technology appraisal recommended budesonide ODT for induction of remission but did not address maintenance. This review assesses the evidence for use in maintenance treatment. Download the full review below to read more.

Cardiovascular outcomes associated with SGLT2 inhibitors (update 2)

The sodium-glucose co-transporter 2 (SGLT2) inhibitors canagliflozin, dapagliflozin, empagliflozin and ertugliflozin are licensed for the improvement of glycaemic control in adults with type 2 diabetes, a population at increased risk of cardiovascular events. Recent clinical trials and cohort studies have assessed whether the SGLT2 inhibitors reduce this risk. Download the full review below to read […]

Cardiovascular outcomes associated with GLP1 receptor agonists (updated)

The glucagon-like peptide 1 receptor agonists (GLP1RAs) dulaglutide, exenatide, liraglutide, lixisenatide, and semaglutide are licensed for the improvement of glycaemic control in adults with type 2 diabetes, a population which is also at increased risk of cardiovascular events. Good quality evidence assessed the effect of these drugs on cardiovascular outcomes. Download the full review below […]